Copaxone competitor on way to European approval
Biogene's Tecfidera becomes the third oral multiple sclerosis treatment on the market, rivaling Teva's injectable Copaxone.
Analysts believe that Biogene's drug, which was called BG-12 in the clinical trial stage, will take a 20% market share worth $3.25 billion annually.
In 2012 Copaxone had annual sales of $4 billion, 19.7% of Teva's overall revenue, and was reportedly responsible for 40-60% of the pharmaceutical company's profit. Thus any harm to Copaxone's market standing raises investor concerns and pushes Teva's share price down.
Tecfidera is set to become the third oral multiple sclerosis treatment on the market after Novartis's Gilenya and Sanofi's Aubagio.
Published by Globes [online], Israel business news - www.globes-online.com - on March 24, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options